{"id":"https://openalex.org/W4308976564","doi":"https://doi.org/10.1093/neuonc/noac209.243","title":"CTIM-11. SINGLE-CENTER, OFF-LABEL NEOADJUVANT PEMBROLIZUMAB FOR TREATMENT OF RECURRENT GBM AT UCLA","display_name":"CTIM-11. SINGLE-CENTER, OFF-LABEL NEOADJUVANT PEMBROLIZUMAB FOR TREATMENT OF RECURRENT GBM AT UCLA","publication_year":2022,"publication_date":"2022-11-01","ids":{"openalex":"https://openalex.org/W4308976564","doi":"https://doi.org/10.1093/neuonc/noac209.243"},"language":"en","primary_location":{"id":"doi:10.1093/neuonc/noac209.243","doi":"https://doi.org/10.1093/neuonc/noac209.243","is_oa":true,"landing_page_url":"https://doi.org/10.1093/neuonc/noac209.243","pdf_url":"https://academic.oup.com/neuro-oncology/article-pdf/24/Supplement_7/vii61/47019315/noac209.243.pdf","source":{"id":"https://openalex.org/S106908163","display_name":"Neuro-Oncology","issn_l":"1522-8517","issn":["1522-8517","1523-5866"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuro-Oncology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://academic.oup.com/neuro-oncology/article-pdf/24/Supplement_7/vii61/47019315/noac209.243.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5019863674","display_name":"Shivani Baisiwala","orcid":"https://orcid.org/0000-0001-5252-9940","observed_orcids":["https://orcid.org/0000-0001-5252-9940"]},"institutions":[{"id":"https://openalex.org/I2801272649","display_name":"Ronald Reagan UCLA Medical Center","ror":"https://ror.org/04k3jt835","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799798094","https://openalex.org/I2801272649"]},{"id":"https://openalex.org/I2801403999","display_name":"UCLA Medical Center","ror":"https://ror.org/04vq5kb54","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799798094","https://openalex.org/I2801403999"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shivani Baisiwala","raw_affiliation_strings":["UCLA Medical Center , Los Angeles, CA , USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCLA Medical Center , Los Angeles, CA , USA","institution_ids":["https://openalex.org/I2801272649","https://openalex.org/I2801403999"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100629345","display_name":"Lu Sun","orcid":"https://orcid.org/0000-0002-6592-1156","observed_orcids":["https://orcid.org/0000-0002-6592-1156"]},"institutions":[{"id":"https://openalex.org/I2801272649","display_name":"Ronald Reagan UCLA Medical Center","ror":"https://ror.org/04k3jt835","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799798094","https://openalex.org/I2801272649"]},{"id":"https://openalex.org/I2801403999","display_name":"UCLA Medical Center","ror":"https://ror.org/04vq5kb54","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799798094","https://openalex.org/I2801403999"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lu Sun","raw_affiliation_strings":["UCLA Medical Center , Los Angeles , USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCLA Medical Center , Los Angeles , USA","institution_ids":["https://openalex.org/I2801272649","https://openalex.org/I2801403999"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025351354","display_name":"Benjamin M. Ellingson","orcid":"https://orcid.org/0000-0002-2764-6640","observed_orcids":["https://orcid.org/0000-0002-2764-6640"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Benjamin Ellingson","raw_affiliation_strings":["UCLA Brain Tumor Imaging Laboratory , Los Angeles, CA , USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCLA Brain Tumor Imaging Laboratory , Los Angeles, CA , USA","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010449744","display_name":"Robert Michael Prins","orcid":"https://orcid.org/0000-0002-6282-6583","observed_orcids":["https://orcid.org/0000-0002-6282-6583"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert Prins","raw_affiliation_strings":["University of California, Los Angeles , Los Angeles , USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of California, Los Angeles , Los Angeles , USA","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038569402","display_name":"Phioanh Leia Nghiemphu","orcid":"https://orcid.org/0000-0003-4064-6079","observed_orcids":["https://orcid.org/0000-0003-4064-6079"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Phioanh L Nghiemphu","raw_affiliation_strings":["University of California Los Angeles , Los Angeles , USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of California Los Angeles , Los Angeles , USA","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063511816","display_name":"Timothy Francis Cloughesy","orcid":"https://orcid.org/0000-0002-8656-7483","observed_orcids":["https://orcid.org/0000-0002-8656-7483"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Timothy Cloughesy","raw_affiliation_strings":["University of California, Los Angeles , Los Angeles, CA , USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of California, Los Angeles , Los Angeles, CA , USA","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5019281368","display_name":"Richard G. Everson","orcid":"https://orcid.org/0000-0003-2809-3061","observed_orcids":["https://orcid.org/0000-0003-2809-3061"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard G Everson","raw_affiliation_strings":["University of California Los Angeles , Los Angeles , USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of California Los Angeles , Los Angeles , USA","institution_ids":["https://openalex.org/I161318765"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4612,"currency":"USD","value_usd":4612},"apc_paid":null,"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.19803741,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"24","issue":"Supplement_7","first_page":"vii61","last_page":"vii62"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0010000000474974513,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11600","display_name":"Brain Metastases and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.9039999842643738},{"id":"https://openalex.org/keywords/recurrent-glioblastoma","display_name":"recurrent glioblastoma","score":0.9810000061988831},{"id":"https://openalex.org/keywords/neoadjuvant-immunotherapy","display_name":"neoadjuvant immunotherapy","score":0.8960000276565552},{"id":"https://openalex.org/keywords/pd-1-inhibitors","display_name":"PD-1 inhibitors","score":0.828000009059906},{"id":"https://openalex.org/keywords/off-label-drug-use","display_name":"off-label drug use","score":0.8700000047683716},{"id":"https://openalex.org/keywords/multiple-recurrence","display_name":"multiple recurrence","score":0.8669999837875366},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9520000219345093},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9990000128746033},{"id":"https://openalex.org/keywords/tumor-microenvironment","display_name":"tumor microenvironment","score":0.843999981880188},{"id":"https://openalex.org/keywords/t-cell-infiltration","display_name":"T cell infiltration","score":0.753000020980835}],"concepts":[{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.889347493648529},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8691275119781494},{"id":"https://openalex.org/C2778292576","wikidata":"https://www.wikidata.org/wiki/Q6991934","display_name":"Neoadjuvant therapy","level":4,"score":0.6888977885246277},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.6455614566802979},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6196263432502747},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5384206175804138},{"id":"https://openalex.org/C2777863537","wikidata":"https://www.wikidata.org/wiki/Q357896","display_name":"Adjuvant","level":2,"score":0.42031192779541016},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2578105330467224},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.25172388553619385},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.16111955046653748}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1093/neuonc/noac209.243","doi":"https://doi.org/10.1093/neuonc/noac209.243","is_oa":true,"landing_page_url":"https://doi.org/10.1093/neuonc/noac209.243","pdf_url":"https://academic.oup.com/neuro-oncology/article-pdf/24/Supplement_7/vii61/47019315/noac209.243.pdf","source":{"id":"https://openalex.org/S106908163","display_name":"Neuro-Oncology","issn_l":"1522-8517","issn":["1522-8517","1523-5866"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuro-Oncology","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1093/neuonc/noac209.243","doi":"https://doi.org/10.1093/neuonc/noac209.243","is_oa":true,"landing_page_url":"https://doi.org/10.1093/neuonc/noac209.243","pdf_url":"https://academic.oup.com/neuro-oncology/article-pdf/24/Supplement_7/vii61/47019315/noac209.243.pdf","source":{"id":"https://openalex.org/S106908163","display_name":"Neuro-Oncology","issn_l":"1522-8517","issn":["1522-8517","1523-5866"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuro-Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4308976564.pdf","grobid_xml":"https://content.openalex.org/works/W4308976564.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W6965155604","https://openalex.org/W2983207864","https://openalex.org/W2961774803","https://openalex.org/W4309017197","https://openalex.org/W4294680086","https://openalex.org/W2911752971","https://openalex.org/W4404237264","https://openalex.org/W2936342011","https://openalex.org/W4403512113","https://openalex.org/W2891636281"],"abstract_inverted_index":{"Abstract":[0],"Neoadjuvant":[1],"drug":[2],"administration":[3,179],"provides":[4],"a":[5,41,108,117],"window":[6],"of":[7,25,97,150,180,205],"opportunity":[8],"for":[9,22,33,78,147,303],"developing":[10],"novel":[11,300],"therapies.":[12],"Specifically,":[13],"neoadjuvant":[14,64,74,99,133,181,207,227,236],"pembrolizumab":[15,52,75,100,134,182,278],"(PD1":[16],"checkpoint":[17],"inhibitor)":[18],"has":[19],"the":[20,29,47,63,95,167,218,234,272],"potential":[21],"improving":[23],"understanding":[24],"immunomodulatory":[26],"effects":[27,61],"on":[28],"tumor":[30,48,282],"microenvironment":[31],"and":[32,93,124,135,143,160,223,279],"treating":[34],"recurrent":[35,79],"GBM.":[36],"It":[37],"is":[38],"known":[39],"that":[40,73,178,256,285],"functional":[42],"immune":[43],"deficit":[44],"exists":[45],"within":[46,138],"T-lymphocyte":[49],"compartment.":[50],"As":[51],"promotes":[53],"lymphocyte":[54],"infiltration,":[55],"it":[56],"may":[57],"contribute":[58],"to":[59,88,127,162,191,214,250],"antitumor":[60],"in":[62,101,183,217,225],"setting.":[65],"Our":[66],"previous":[67],"randomized":[68],"clinical":[69],"trial":[70],"(RCT)":[71],"suggested":[72],"improved":[76],"survival":[77,145],"GBM":[80,118],"patients":[81,102,152,257,305],"with":[82,103,258,291,306],"1-2":[83],"relapses.":[84],"Here,":[85],"we":[86],"sought":[87],"extend":[89],"our":[90,148,184,192,206,226,245],"original":[91,168],"findings":[92],"analyze":[94],"role":[96],"off-label":[98,132],"multiple":[104,307],"recurrences.":[105,129,308],"We":[106,294],"identified":[107],"retrospective":[109],"22-patient":[110],"cohort":[111,149,185,208,228,237,246],"at":[112],"UCLA.":[113],"Every":[114],"patient":[115],"had":[116,125],"tissue":[119],"diagnosis,":[120],"received":[121,131],"standard":[122],"treatment,":[123],"one":[126],"five":[128],"Each":[130],"surgical":[136,158],"resection":[137,159],"7-21":[139],"days.":[140],"Progression-free":[141],"(PFS)":[142],"overall":[144],"(OS)":[146],"neoadjuvant-treated":[151],"were":[153,229],"calculated":[154],"as":[155,212],"days":[156,211,216],"from":[157,166,265],"compared":[161,190,213],"historical":[163,193,219,235],"control":[164,195],"data":[165,254],"RCT":[169],"(n":[170],"=":[171,201,239,242],"15":[172,174],"neoadjuvant,":[173],"adjuvant).":[175],"Results":[176],"show":[177],"significantly":[186],"increased":[187],"median":[188],"PFS":[189,222],"adjuvant":[194],"(114":[196],"vs":[197],"75":[198],"days,":[199],"p":[200],"0.03).":[202],"The":[203],"OS":[204,224],"was":[209,247],"294":[210],"192":[215],"control.":[220],"Both":[221],"not":[230,248],"statistically":[231],"different":[232],"than":[233],"(PFSp":[238],"0.08,":[240],"OSp":[241],"0.13).":[243],"Since":[244],"limited":[249],"initial":[251],"recurrences,":[252],"this":[253,296],"suggests":[255],"more":[259],"advanced":[260],"recurrences":[261],"could":[262],"also":[263],"benefit":[264],"neo-adjuvant":[266],"therapy.":[267],"Ongoing":[268],"work":[269],"will":[270],"evaluate":[271],"microenvironmental":[273],"genetic":[274],"signature":[275],"induced":[276],"by":[277],"assess":[280],"pre-surgical":[281],"volume":[283],"so":[284],"adequate":[286],"comparisons":[287],"can":[288],"be":[289],"made":[290],"other":[292],"trials.":[293],"believe":[295],"promising":[297],"finding":[298],"offers":[299],"therapeutic":[301],"options":[302],"those":[304]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2022-11-20T00:00:00"}